Cell- and Single Molecule-Based Methods to Detect Anti-N-Methyl-D-Aspartate Receptor Autoantibodies in Patients With First-Episode Psychosis From the OPTiMiSE Project.

Julie Jézéquel, Véronique Rogemond, Thomas Pollak, Marilyn Lepleux, Leslie Jacobson, Hélène Gréa, Conrad Iyegbe, Rene Kahn, Philip McGuire, Angela Vincent, Jérôme Honnorat, Marion Leboyer, Laurent Groc
Biological Psychiatry. 2017-11-01; 82(10): 766-772
DOI: 10.1016/j.biopsych.2017.06.015

PubMed

Lire sur PubMed

https://www.bordeaux-neurocampus.fr/12292

Jézéquel J(1), Rogemond V(2), Pollak T(3), Lepleux M(1), Jacobson L(4), Gréa H(1), Iyegbe C(3), Kahn R(5), McGuire P(3), Vincent A(4), Honnorat J(2), Leboyer M(6), Groc L(7).

Author information:
(1)Interdisciplinary Institute for Neuroscience, UMR 5297, University of
Bordeaux, France; Centre National de la Recherche Scientifique, France.
(2)Institut NeuroMyoGène, Institut National de la Santé et de la Recherche
Médicale U1217/Centre National de la Recherche Scientifique UMR 5310, Lyon,
France; Hôpital Neurologique, France.
(3)King’s Health Partners, Institute of Psychiatry, Psychology and Neuroscience,
King’s College London, London, UK.
(4)Nuffield Department of Clinical Neurosciences, Neurosciences Group,
Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
(5)Department of Psychiatry, Brain Center Rudolf Magnus, University Medical
Center Utrecht, Utrecht, The Netherlands.
(6)Department of Psychiatry, University Paris Est Créteil, Hopitaux
Universitaires Henri Mondor, AP-HP, DHU PePSY, Créteil, France; FondaMental
Foundation, Créteil, France.
(7)Interdisciplinary Institute for Neuroscience, UMR 5297, University of
Bordeaux, France; Centre National de la Recherche Scientifique, France.
Electronic address: .

Circulating autoantibodies against glutamatergic N-methyl-D-aspartate receptor
(NMDAR) have been reported in a proportion of patients with psychotic disorders,
raising hopes for more appropriate treatment for these antibody-positive
patients. However, the prevalence of circulating autoantibodies against
glutamatergic NMDAR in psychotic disorders remains controversial, with detection
prevalence rates and immunoglobulin classes varying considerably between
studies, perhaps because of different detection methods. Here, we compared the
results of serum assays for a large cohort of patients with first-episode
psychosis using classical cell-based assays in three labs and a single
molecule-based imaging method. Most assays and single molecule imaging in live
hippocampal neurons revealed the presence of circulating autoantibodies against
glutamatergic NMDAR in approximately 5% of patients with first-episode
psychosis. However, some heterogeneity between cell-based assays was clearly
observed, highlighting the urgent need for new sensitive methods to detect the
presence of low-titer autoantibodies against glutamatergic NMDAR in seropositive
patients who cannot be clinically identified from seronegative ones.